



## Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

September 15, 2021

### Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3<sup>rd</sup> Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference's scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company's development-stage KRAS<sup>G12C</sup>(ON) inhibitor, will each deliver a scientific presentation as part of the conference.

Details of Revolution Medicines' participation in the 3<sup>rd</sup> Annual RAS-Targeted Drug Development Summit are as follows:

#### Presentations:

**Title:** Targeting KRAS<sup>G12C</sup>(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors  
**Presenter:** Bob Nichols, Ph.D., project lead for RMC-6291  
**Date:** Wednesday, September 22, 2021  
**Time:** 11:55 a.m. Eastern

**Title:** Combination Strategies to Defeat RAS-Addicted Cancers  
**Presenter:** Jan Smith, Ph.D., senior vice president, biology  
**Date:** Wednesday, September 22, 2021  
**Time:** 2:00 p.m. Eastern

#### Panel Discussion:

**Title:** On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510  
**Moderator:** Steve Kelsey, M.D., president, research and development  
**Date:** Thursday, September 23, 2021  
**Time:** 4:15 p.m. Eastern

#### Scientific Track:

**Title:** Validating Robust Combination Strategies  
**Chairperson:** Steve Kelsey, M.D., president, research and development  
**Date/Time:** Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern  
Thursday, September 23, 2021; 11:00 a.m. – 12:30 p.m. Eastern

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at <https://ras-drugdevelopment.com/>

#### **About Revolution Medicines, Inc.**

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

#### **Contacts:**

For Investors:  
**Vida Strategic Partners**  
Stephanie Diaz  
415-675-7401  
[sdiaz@vidasp.com](mailto:sdiaz@vidasp.com)

For Media:  
**Vida Strategic Partners**  
Tim Brons  
415-675-7402  
[tbrons@vidasp.com](mailto:tbrons@vidasp.com)